Concepedia

Mehmet Bilici

MB

Statistics

Publications

40

Citations

2.2K

H-Index

20

Active since

2005

Affiliations

Atatürk University(Current)

Memorial Sloan Kettering Cancer Center

Yonsei University

The Maria Sklodowska-Curie National Research Institute of Oncology

KU Leuven

Mehmet Bilici is an author at Atatürk University specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2005–2025

40

Publications

40

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai et al. · The Lancet · 2023 · 467 citations

, , +17

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

, , +12

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg et al. · New England Journal of Medicine · 2025 · 223 citations

, , +14

Clinical significance of prognostic nutritional index (PNI) in malignant melanoma

Cem Mirili, Ali Yılmaz, Serkan Demirkan et al. · International Journal of Clinical Oncology · 2019 · 113 citations

, , +16

Antiulcer activity of fluvoxamine in rats and its effect on oxidant and antioxidant parameters in stomach tissue

Hakan Dursun, Mehmet Bilici, Fatih Albayrak et al. · BMC Gastroenterology · 2009 · 88 citations · Full text

, , +14

1–5 of 40